Hovione and Particle Sciences Inc (PSI) have entered a collaboration to combine their technologies in an effort to speed development projects targeting poorly water-soluble drugs. The two companies will use their solid solution technologies based on spray-drying capabilities to target ways of maximizing the bioavailability of BCS Class II APIs. PSI will develop the solubilization process and resulting drug product and Hovione will manage the scale-up and industrialization of the spray drying process for clients.
 
Dave Hoffman, president, Hovione U.S. Operations, said, “It is truly incredible how versatile and useful spray-drying technology is. We have used it from a gram scale to tons, with important time savings on the scale-up to manufacture products where other technologies failed. Teaming up with PSI will give their customers an integrated solution which will allow us to go from drug product and process design to feasibility and development to industrial application in record time.”
 
According to Mark Mitchnick, Particle Sciences’ chief executive officer, “We have a variety of drug delivery platforms, some of which are best scaled through spray drying. Our unique contribution is to develop products that maximize clinical effect, and after that Hovione takes over with their technological and industrial expertise and regulatory compliance. We will really be able to save our clients quite a lot of time.”